Padcev (enfortumab vedotin) for the Treatment of Urothelial Cancer

Image 1-Padcev
Padcev™ (enfortumab vedotin) is the first approved nectin-4-directed antibody-drug conjugate to treat advanced urothelial cancer. Credit: Business Wire.